{"id":70770,"date":"2026-05-12T10:58:38","date_gmt":"2026-05-12T10:58:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70770"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"hgh-191aa","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/hgh-191aa\/","title":{"rendered":"HGH 191AA"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que l'HGH 191AA ?<\/h3>\n<p style=\"margin: 0;\"><strong>HGH 191AA<\/strong> is recombinant human growth hormone in its full 191-amino-acid native sequence form (somatropin), a 22-kDa pituitary peptide hormone produced by recombinant DNA technology to exactly match the endogenous human GH polypeptide. It acts directly on the growth hormone receptor (GHR) to activate JAK2\/STAT5 signalling and drive hepatic IGF-1 production. This is the modern pharmaceutical-quality form (191AA) as opposed to the obsolete bacterial 192AA recombinant variant. Supplied in 10\u201340\u00a0IU lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">12629-01-5 (somatropine) \/ 96827-07-5 (somatropine recombinante)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Type<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prot\u00e9ine recombinante \u2014 s\u00e9quence native de l'hormone de croissance humaine \u00e0 191 acides amin\u00e9s (somatropine) ; DCI : somatropine<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">22 124 Da (~22 kDa)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Structure<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cha\u00eene polypeptidique unique \u00e0 191 acides amin\u00e9s repli\u00e9e en une topologie canonique \u00e0 quatre faisceaux h\u00e9lico\u00efdaux, stabilis\u00e9e par deux ponts disulfure intramol\u00e9culaires (Cys53\u2013Cys165 et Cys182\u2013Cys189). La d\u00e9signation 191AA distingue la forme pharmaceutique moderne de qualit\u00e9 de l'ancienne variante recombinante bact\u00e9rienne 192AA qui portait une m\u00e9thionine N-terminale suppl\u00e9mentaire.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Activit\u00e9 unitaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Approximativement 3 UI par mg de HGH recombinante 191AA (unit\u00e9s internationales, norme OMS)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prot\u00e9ine recombinante lyophilis\u00e9e (poudre blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226598 % (v\u00e9rifi\u00e9 par HPLC, certificat d'analyse sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, utiliser dans les ~14 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e \u2014 les prot\u00e9ines recombinantes sont particuli\u00e8rement sensibles \u00e0 la d\u00e9naturation par cong\u00e9lation-d\u00e9cong\u00e9lation.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e). Prot\u00e9ine porteuse (BSA, 0,1 %) facultative pour les dilutions de travail afin de minimiser les pertes par adsorption.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que la HGH 191AA ?<\/h2>\n<p><strong>HGH 191AA<\/strong> is recombinant human growth hormone (somatropin) in the 191-amino-acid native human sequence form. It is produced by recombinant DNA technology and matches the endogenous human GH polypeptide exactly \u2014 same 191 amino acids, same four-helix bundle three-dimensional structure, same two intramolecular disulfide bonds at Cys53\u2013Cys165 and Cys182\u2013Cys189. The 191AA designation specifically distinguishes the modern pharmaceutical-quality recombinant form from the older 192AA variant produced in bacterial expression systems, which carried an additional N-terminal methionine that introduced minor antigenicity differences and has been largely phased out of studies and clinical use. HGH is the principal peptide hormone secreted by somatotroph cells of the anterior pituitary in episodic pulses, with peak amplitudes occurring during early slow-wave sleep and following intense exercise. Endogenous secretion is regulated upstream by hypothalamic GHRH (positive) and somatostatin (negative). The recombinant 191AA form has empirical molecular weight 22,124\u00a0Da, INN somatropin, CAS number 12629-01-5 for the native protein and 96827-07-5 for the recombinant form. Standard unit activity for recombinant 191AA HGH is approximately 3\u00a0IU per mg according to the WHO International Standard. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. HGH is the most stringently regulated of all peptides in many jurisdictions and is approved for specific medical indications (paediatric GH deficiency, adult GH deficiency, Turner syndrome, idiopathic short stature, AIDS wasting, short bowel syndrome) only under prescription. For peptides that stimulate endogenous GH release rather than supplying exogenous GH, see our <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a>, et <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> pages produit. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Signalisation du r\u00e9cepteur de l'hormone de croissance et l'axe GH\/IGF<\/h2>\n<p>What makes HGH 191AA mechanistically distinctive among peptides is that it is the <strong>ligand exog\u00e8ne direct<\/strong> for the growth hormone receptor \u2014 not an analog, not a secretagogue, but the native polypeptide itself. The downstream signalling cascade has been characterised across decades of published studies:<\/p>\n<ul>\n<li><strong>Liaison au r\u00e9cepteur de l'hormone de croissance (GHR) et homodim\u00e9risation<\/strong> \u2014 La HGH se lie \u00e0 une seule mol\u00e9cule de GHR avec une haute affinit\u00e9 et induit l'homodim\u00e9risation avec une deuxi\u00e8me unit\u00e9 r\u00e9ceptrice, formant le complexe ligand-r\u00e9cepteur bioactive 1:2. Le r\u00e9cepteur dim\u00e9ris\u00e9 recrute la Janus kinase 2 cytoplasmique (JAK2) au motif de bo\u00eete r\u00e9ceptrice intracellulaire, conduisant \u00e0 la trans-phosphorylation de JAK2 et du r\u00e9cepteur lui-m\u00eame. C'est le m\u00e9canisme d'activation canonique du r\u00e9cepteur de cytokine de type I.<\/li>\n<li><strong>Activation du facteur de transcription JAK2\/STAT5<\/strong> \u2014 La JAK2 phosphoryl\u00e9e phosphoryle le transducteur de signal et activateur de transcription 5 (STAT5), principalement STAT5b, qui se dim\u00e9rise ensuite et se transloque vers le noyau o\u00f9 il se lie aux promoteurs de g\u00e8nes sensibles \u00e0 l'hormone de croissance (GH). La principale r\u00e9ponse transcriptionnelle est l'induction de l'expression de l'IGF-1 (Insulin-like Growth Factor 1) dans les h\u00e9patocytes \u2014 l'effecteur endocrinien principal des effets p\u00e9riph\u00e9riques de promotion de la croissance de la GH. Parmi les autres g\u00e8nes sensibles \u00e0 la GH figurent les prot\u00e9ines SOCS (r\u00e9troaction n\u00e9gative), CIS et un programme de g\u00e8nes de synth\u00e8se des prot\u00e9ines h\u00e9patiques.<\/li>\n<li><strong>Effets tissulaires directs et indirects (m\u00e9di\u00e9s par l'IGF-1)<\/strong> \u2014 La GH a deux modes d'action principaux. <em>Effets directs<\/em>: lipolysis at adipocytes, glucose-counter-regulatory effects opposing insulin in muscle and liver, and direct anabolic signalling at GHR-expressing tissues including chondrocytes (in long-bone growth-plate studies) and immune cells. <em>Effets indirects via l'IGF-1<\/em>: hepatic IGF-1 acts at the IGF-1 receptor on essentially every cell type to drive Akt\/mTOR-mediated protein synthesis, cell proliferation, and survival signalling. The compound <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> est l'outil canonique de r\u00e9cepteur direct de l'IGF utilis\u00e9 pour dissocier les effets directs de la GH des effets en aval m\u00e9di\u00e9s par l'IGF-1.<\/li>\n<\/ul>\n<p>HGH has a relatively short plasma half-life (~3\u20135 hours following subcutaneous administration of the native protein) due to renal filtration and proteolytic clearance. The pulsatile pattern of endogenous secretion is a defining feature of the GH axis \u2014 tonic continuous exposure to GH produces different downstream gene-expression patterns than pulsatile exposure, an important consideration in protocol design. Subcutaneous administration is the standard administration route. For endogenous-pulse-pattern studies, secretagogues like <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295<\/a>, et <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> pr\u00e9servent la signature pulsatile naturelle ; pour la pharmacologie directe du r\u00e9cepteur de la GH, la HGH exog\u00e8ne fournit le stimulus plus propre. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH 191AA is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Pharmacologie de l'axe de l'hormone de croissance<\/strong> \u2014 direct GHR signalling, JAK2\/STAT5 phosphorylation kinetics, downstream IGF-1 induction; canonical peptide for the GH side of the GH\/IGF-1 axis<\/li>\n<li><strong>IGF-1 induction studies<\/strong> \u2014 expression g\u00e9nique de l'IGF-1 h\u00e9patique, dynamique de l'IGF-1 circulant, r\u00e9gulation des prot\u00e9ines de liaison \u00e0 l'IGF (IGFBP) ; comparateur pour <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a>-based studies that bypasses the GH step<\/li>\n<li><strong>Anabolic signalling studies<\/strong> \u2014 synth\u00e8se des prot\u00e9ines du muscle squelettique via Akt\/mTOR (principalement m\u00e9di\u00e9e par IGF-1), signalisation des chondrocytes de la plaque de croissance osseuse, lipolyse du tissu adipeux<\/li>\n<li><strong>Hepatic metabolism studies<\/strong> \u2014 production de glucose par le foie, m\u00e9tabolisme des lipides, r\u00e9ponse transcriptionnelle sp\u00e9cifique des h\u00e9patocytes \u00e0 la stimulation par GH<\/li>\n<li><strong>Mod\u00e8les pr\u00e9cliniques de d\u00e9ficience en GH<\/strong> \u2014 \u00e9tudes de sauvetage chez des rongeurs hypophysectomis\u00e9s, mod\u00e8les de souris naines Snell et Ames, caract\u00e9risation des knockouts transg\u00e9niques du r\u00e9cepteur de GH<\/li>\n<li><strong>Sleep and circadian rhythm support<\/strong> \u2014 relation entre l'architecture du sommeil et la s\u00e9cr\u00e9tion pulsatile de GH, d\u00e9pendance de la GH au sommeil lent profond<\/li>\n<li><strong>Comparative GH-axis studies<\/strong> \u2014 comparaison avec les analogues de la GHRH (<a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295<\/a>) et les s\u00e9cr\u00e9tagogues de l'hormone de croissance (<a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/ghrp-6\/\">GHRP-6<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/ghrp-2\/\">GHRP-2<\/a>) qui produisent des pulses endog\u00e8nes de GH plut\u00f4t qu'un remplacement exog\u00e8ne de GH<\/li>\n<li><strong>Tissue regeneration and wound healing studies<\/strong> \u2014 litt\u00e9rature publi\u00e9e sur les effets de la GH dans les mod\u00e8les de br\u00fblures, la r\u00e9cup\u00e9ration post-chirurgicale et la r\u00e9g\u00e9n\u00e9ration tissulaire ; relation avec <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> healing peptide studies<\/li>\n<li><strong>Endocrinology and aging studies<\/strong> \u2014 somatopause and age-related GH decline, comparative studies of GH replacement vs GH-axis stimulation in aging study models.<\/li>\n<\/ul>\n<p>Pour un contexte plus large sur la place de l'HGH 191AA dans le paysage des peptides de l'axe de croissance, voir <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> comme comparateurs de l'axe GHRH, <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> comme comparateur s\u00e9lectif des GHS, et <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> comme agoniste des r\u00e9cepteurs de l'IGF en aval. Parcourez l'int\u00e9gralit\u00e9 du <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks HGH 191AA in five lyophilized vial sizes calibrated by international units (IU). Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosage du flacon (UI)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Masse approximative<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3.3\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dosage pilote, titration de bas niveau, protocoles \u00e0 cycle court<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15\u00a0IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~5\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, mid-titration arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>24\u00a0IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~8\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, higher-dose titration arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>36\u00a0IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~12\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocoles multi-semaines \u00e0 partir d'un seul flacon, volume de reconstitution r\u00e9duit par dose<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40\u00a0IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~13.3\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, lowest per-IU cost, multi-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All five strengths are the same chemical form (lyophilized recombinant 191AA somatropin, \u226598% HPLC purity). The IU labelling convention is the standard for HGH studies and clinical literature; the approximate mg equivalents are provided for users calibrating dose against mg-based literature. Higher-IU vials require smaller reconstitution volumes per unit dose, useful for minimising injection volume in rodent protocols or running extended-cycle studies from a single vial. <\/p>\n<h2>Comment il se compare \u2014 HGH 191AA vs Sermorelin<\/h2>\n<p>HGH 191AA et <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> represent the two opposing pharmacological approaches to GH-axis studies: exogenous GH replacement vs endogenous GH stimulation. The comparison is one of the most-cited in growth-axis studies design because the two approaches answer different studies questions and produce qualitatively different downstream phenotypes. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Sermorelin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Ce que c'est<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">La GH exog\u00e8ne elle-m\u00eame (recombinante)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Analogue de GHRH(1-29) \u2014 stimule la GH endog\u00e8ne<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191 acides amin\u00e9s (~22 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">29 acides amin\u00e9s (~3 kDa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mode d'action<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonisme direct du GHR (remplacement)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonisme (stimulation) du r\u00e9cepteur hypothalamique de la GHRH<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mod\u00e8le de pulsation de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Exposition tonique apr\u00e8s chaque injection<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pulsatile (pr\u00e9serve le rythme naturel)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>R\u00e9troaction n\u00e9gative<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Contourn\u00e9 (supprime les somatotrophes endog\u00e8nes)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pr\u00e9serv\u00e9 (la somatostatine reste active)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 heures (SC)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~10\u201320 minutes (tr\u00e8s court)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Utilisation clinique approuv\u00e9e<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Indications multiples approuv\u00e9es (Genotropin, Humatrope, Norditropin, etc.)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Approbation historique de la FDA pour le GHD p\u00e9diatrique (Geref) ; abandonn\u00e9<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20138\u00a0UI par administration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100\u2013500 mcg par administration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in direct GHR pharmacology, IGF-1 induction kinetics, or replacing GH in deficiency models, HGH 191AA is the canonical tool because it provides the exogenous ligand directly. For studies interested in physiological pulsatile GH dynamics, hypothalamic-pituitary-axis pharmacology, or any protocol where preserving the natural somatostatin feedback loop matters, <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> (et les apparent\u00e9s <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a>) provide the upstream-stimulation alternative. Many published studies designs use both in parallel arms to dissect direct GH effects from secretagogue-stimulated endogenous GH effects. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C dans leur emballage d'origine pour un stock de travail \u00e0 court terme. Pour un stockage \u00e0 long terme non ouvert, congeler \u00e0 -20 \u00b0C. La GH recombinante lyophilis\u00e9e reste stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 -20 \u00b0C jusqu'\u00e0 36 mois. La structure en faisceau \u00e0 quatre h\u00e9lices est pr\u00e9serv\u00e9e sous forme lyophilis\u00e9e. \u00c9viter les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre lyophilis\u00e9e. <strong>Proc\u00e9dure de reconstitution :<\/strong> injectez l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon (pas directement sur la poudre lyophilis\u00e9e). Les volumes de reconstitution recommand\u00e9s varient selon la concentration du flacon \u2014 pour un flacon de 10\u00a0UI, 1,0\u00a0mL d'eau bact\u00e9riostatique donne une concentration de travail de 10\u00a0UI\/mL ; pour un flacon de 36\u00a0UI, 1,5\u00a0mL donne 24\u00a0UI\/mL. Agitez doucement \u2014 ne <strong>re\u00e7oit pas<\/strong> Agitez \u2014 et laissez 5 \u00e0 10 minutes pour une dissolution compl\u00e8te. Les prot\u00e9ines recombinantes se dissolvent plus lentement que les petits peptides ; ne pr\u00e9cipitez pas l'\u00e9tape de dissolution. Un secouage vigoureux peut perturber la structure en faisceau \u00e0 quatre h\u00e9lices et r\u00e9duire l'activit\u00e9. Une solution correctement reconstitu\u00e9e doit \u00eatre claire et incolore, sans particules visibles. <strong>Apr\u00e8s reconstitution :<\/strong> conserver au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C et utiliser dans les 14 jours pour une stabilit\u00e9 optimale \u2014 l\u00e9g\u00e8rement plus court que la fen\u00eatre de 30 jours pour les petits peptides synth\u00e9tiques, car la prot\u00e9ine \u00e0 quatre h\u00e9lices de plus grande taille est plus sensible aux pertes par adsorption de surface et \u00e0 la d\u00e9samidation lente. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation entra\u00eenent une agr\u00e9gation et une perte d'activit\u00e9 biologique. Jeter tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. Pour les dilutions de travail prolong\u00e9es en dessous de 0,1 mg\/mL (~0,3 UI\/mL), une prot\u00e9ine porteuse (BSA \u00e0 une concentration finale de 0,1 %) minimise les pertes par adsorption. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is HGH 191AA used for in studies?<\/h3>\n<p>HGH 191AA is used in studies investigating direct growth hormone receptor pharmacology, JAK2\/STAT5 signalling, hepatic IGF-1 induction, anabolic signalling in muscle and bone, hepatic metabolism, sleep-GH-axis relationships, GH-deficiency preclinical models, and comparative GH-axis pharmacology against GHRH analogs and growth hormone secretagogues. It is the canonical exogenous GH tool. The pharmaceutical-grade HGH 191AA sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved for non-clinical human use and is supplied strictly for clinical studies use only. <\/p>\n<h3>Quelle est la diff\u00e9rence entre l'HGH 191AA et la 192AA ?<\/h3>\n<p>The 191AA form is the modern pharmaceutical-quality recombinant human growth hormone matching the exact native human sequence (191 amino acids). The 192AA form was an older bacterial-recombinant variant with an additional N-terminal methionine residue (192 amino acids total) that was used in early pharmaceutical development before mammalian-cell expression systems became standard. The extra methionine produced minor antigenicity in some patient populations and the 192AA form has been largely phased out of both studies and clinical use. All pharmaceutical-grade HGH from MedsBase is the 191AA native-sequence form. <\/p>\n<h3>En quoi l'HGH 191AA diff\u00e8re-t-elle de la Sermor\u00e9line ?<\/h3>\n<p>Le HGH 191AA est l'hormone de croissance exog\u00e8ne elle-m\u00eame \u2014 le ligand actif du r\u00e9cepteur. <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> is a 29-amino-acid analog of GHRH (growth hormone releasing hormone) that stimulates the pituitary to release ENDOGENOUS GH. The downstream effects are similar in direction but qualitatively different: HGH produces tonic GHR exposure following each injection and bypasses pituitary feedback, while sermorelin produces a pulsatile GH release pattern and preserves natural somatostatin feedback regulation. Studies designs typically use one or the other depending on whether the question is about direct GHR pharmacology (HGH) or hypothalamic-pituitary-axis dynamics (sermorelin). <\/p>\n<h3>En quoi l'HGH 191AA diff\u00e8re-t-elle de l'IGF-1 LR3 ?<\/h3>\n<p>L'HGH 191AA agit sur le r\u00e9cepteur GH, ce qui stimule la production d'IGF-1 par le foie en tant que principal effecteur en aval. <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> bypasses this step and acts directly on the IGF-1 receptor. HGH studies the full GH\/IGF-1 axis including the upstream liver-mediated IGF-1 induction; IGF-1 LR3 isolates the IGF-receptor pharmacology and the direct downstream Akt\/mTOR anabolic signalling. Both compounds are frequently used in parallel arms of the same studies design to dissect direct GH effects from IGF-1-mediated effects. <\/p>\n<h3>What is the typical HGH 191AA dose?<\/h3>\n<p>Published preclinical studies dose ranges are typically 1\u20138\u00a0IU per administration in rodent and primate models, given subcutaneously once daily or pulsed to mimic endogenous secretion patterns. A 10\u00a0IU vial reconstituted with 1.0\u00a0mL bacteriostatic water yields 10\u00a0IU\/mL \u2014 0.1\u00a0mL equals 1\u00a0IU, 0.2\u00a0mL equals 2\u00a0IU. The conversion factor is approximately 3\u00a0IU per mg of recombinant 191AA HGH (WHO international standard). <\/p>\n<h3>L'HGH 191AA est-elle approuv\u00e9e par la FDA ?<\/h3>\n<p>Pharmaceutical recombinant 191AA HGH (somatropin) is FDA-approved under multiple brand names (Genotropin, Humatrope, Norditropin, Saizen, Omnitrope, Nutropin and others) for specific medical indications including paediatric growth hormone deficiency, adult GH deficiency, Turner syndrome, idiopathic short stature, AIDS-associated wasting, and short bowel syndrome \u2014 only under prescription and supervision by an endocrinologist. It is the most stringently regulated of all peptides in many jurisdictions. <\/p>\n<h3>Comment conserver l'HGH 191AA ?<\/h3>\n<p>Flacons lyophilis\u00e9s : r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C pour le stock de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 14 jours (dur\u00e9e plus courte que pour les petits peptides typiques en raison de la plus grande sensibilit\u00e9 de la structure \u00e0 quatre h\u00e9lices \u00e0 l'adsorption de surface et \u00e0 la d\u00e9samidation lente). Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation provoquent une agr\u00e9gation et une perte d'activit\u00e9. Prot\u00e9ger de la lumi\u00e8re directe en permanence. <\/p>\n<h3>Comment reconstituer l'HGH 191AA ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 5 \u00e0 10 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> secouer le flacon \u2014 une agitation vigoureuse peut perturber la structure \u00e0 quatre h\u00e9lices et r\u00e9duire l'activit\u00e9 biologique. Une solution correctement reconstitu\u00e9e est claire et incolore, sans particules visibles. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries HGH 191AA in 10\u00a0IU, 15\u00a0IU, 24\u00a0IU, 36\u00a0IU, and 40\u00a0IU lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226598% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Pourquoi l'HGH est-elle mesur\u00e9e en UI plut\u00f4t qu'en mg ?<\/h3>\n<p>International Units (IU) are the standard measurement for biological-activity-based labelling of protein hormones, established by the WHO International Standard. For recombinant 191AA HGH, the conversion factor is approximately 3\u00a0IU per mg. The IU labelling convention is preferred because it directly references biological potency rather than mass, which is more reproducible across different recombinant production batches that may vary slightly in glycosylation state, deamidation profile, and folding-state heterogeneity. Both IU and mg are valid; the IU is the dominant unit in clinical and literature. <\/p>\n<h3>Pourquoi la sp\u00e9cification de puret\u00e9 est-elle de 98% plut\u00f4t que 99% ?<\/h3>\n<p>Recombinant proteins like HGH cannot always achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of inherent heterogeneity in any recombinant expression system \u2014 minor variants in folding state, deamidation isoforms, and other related species appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226598% HPLC purity is a strong pharmaceutical-grade specification for recombinant 191AA HGH, intermediate between the 95% common for larger glycoproteins like <a href=\"https:\/\/medsbase.com\/fr\/follistatin-344\/\">Follistatine 344<\/a> et le 99% courant pour les petits peptides synth\u00e9tiques. <\/p>\n<h3>Does HGH 191AA cause side reported effects?<\/h3>\n<p>The principal on-target effects of HGH in study models are anabolic and metabolic: increased IGF-1 levels, increased lean body mass, decreased adiposity, transient insulin resistance, sodium and water retention, and increased mitogenic signalling. At supraphysiological exposures, off-target effects include carpal tunnel symptoms in primate models, glucose dysregulation, and (with chronic exposure) joint and soft-tissue overgrowth. The very strict regulatory framework around HGH for human use reflects these on-target risks at non-physiological doses. <\/p>\n<h3>Quelle est la demi-vie de l'HGH 191AA ?<\/h3>\n<p>In preclinical studies, recombinant HGH has a plasma half-life of approximately 3\u20135 hours following subcutaneous administration. The relatively short half-life reflects renal filtration (a 22-kDa protein is at the boundary of the glomerular filtration cutoff) and proteolytic clearance. Tissue half-life is longer because GHR-bound HGH persists at the cell surface for some time before internalisation. For protocols requiring sustained exposure, repeated daily dosing or specialised long-acting formulations would be needed; the standard recombinant 191AA form does not provide multi-day exposure from a single injection. <\/p>\n<h3>How long does HGH 191AA take to show effects in preclinical studies?<\/h3>\n<p>Les effets aigus sur la phosphorylation de JAK2\/STAT5 et le programme de transcription imm\u00e9diatement sensible \u00e0 la GH sont d\u00e9tectables quelques heures apr\u00e8s l'administration. L'induction h\u00e9patique de l'IGF-1 atteint son pic dans les 24 heures. Les effets sur la composition corporelle (masse maigre, masse adipeuse) deviennent g\u00e9n\u00e9ralement statistiquement significatifs apr\u00e8s 2 \u00e0 4 semaines de dosage r\u00e9gulier dans les mod\u00e8les rongeurs et continuent de s'accumuler jusqu'\u00e0 8 \u00e0 12 semaines d'administration continue. <\/p>\n<h3>Puis-je commander de l'HGH 191AA pour une exp\u00e9dition internationale ?<\/h3>\n<p>Oui, l\u00e0 o\u00f9 les r\u00e9glementations locales le permettent. MedsBase exp\u00e9die l'HGH 191AA dans le monde entier depuis notre r\u00e9seau d'exp\u00e9dition d\u00e9di\u00e9 aux peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. Note that HGH is the most stringently regulated peptide in many jurisdictions \u2014 please verify that local laws permit acquisition in your destination country before ordering. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Growth-Axis, GH-Release, and Anabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Analogue de GHRH(1-29) \u2014 stimule la lib\u00e9ration endog\u00e8ne de GH<\/li>\n<li><a href=\"\/fr\/cjc-1295-with-dac\/\"><strong>CJC-1295 avec DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 canonical long-half-life GHRH use<\/li>\n<li><a href=\"\/fr\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Secr\u00e9tagogue s\u00e9lectif de l'hormone de croissance \u2014 pic de GH propre sans cortisol\/prolactine<\/li>\n<li><a href=\"\/fr\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Analogue recombinant de l'IGF-1 \u00e0 longue arginine \u2014 contourne l'\u00e9tape de la GH<\/li>\n<li><a href=\"\/fr\/ghrp-6\/\"><strong>GHRP-6<\/strong><\/a> \u2014 First-generation hexapeptide GHS \u2014 ghrelin-axis GH release studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explorez l'axe de l'hormone de croissance<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s apparent\u00e9s de l'axe GH incluant <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> for endogenous-pulse studies, <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> for selective GHS studies, and <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> pour le bras aval de l'axe IGF.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Hormone de croissance humaine recombinante (somatropine) de 191 aa<br \/>\n\u2705 S\u00e9quence humaine native \u2014 forme pharmaceutique moderne de qualit\u00e9<br \/>\n\u2705 Agoniste direct du r\u00e9cepteur GH (~22 kDa)<br \/>\n\u2705 Standard ~3 UI par mg conversion<br \/>\n\u2705 Puret\u00e9 \u226598% en HPLC, COA sur demande<\/p>\n<p><strong>HGH 191AA<\/strong> est une prot\u00e9ine recombinante.<\/p>","protected":false},"featured_media":70958,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,5441],"class_list":["post-70770","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70770"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70958"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70770"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70770"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70770"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}